OPK Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of 14.34% compared to OPKO Health's net margin of --. OPKO Health's return on equity of -9.71% beat Perspective Therapeutics's return on equity of --.

OPKO Health has a consensus price target of --, signalling upside risk potential of 155.38%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than OPKO Health, analysts believe Perspective Therapeutics is more attractive than OPKO Health.

OPKO Health has a beta of 1.616, which suggesting that the stock is 61.573% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

OPKO Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OPKO Health pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

OPKO Health quarterly revenues are $173.6M, which are larger than Perspective Therapeutics quarterly revenues of --. OPKO Health's net income of $24.9M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, OPKO Health's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health is 1.72x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Innerscope Hearing Technologies has a net margin of 14.34% compared to OPKO Health's net margin of --. OPKO Health's return on equity of -9.71% beat Innerscope Hearing Technologies's return on equity of --.

OPKO Health has a consensus price target of --, signalling upside risk potential of 155.38%. On the other hand Innerscope Hearing Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that OPKO Health has higher upside potential than Innerscope Hearing Technologies, analysts believe OPKO Health is more attractive than Innerscope Hearing Technologies.

OPKO Health has a beta of 1.616, which suggesting that the stock is 61.573% more volatile than S&P 500. In comparison Innerscope Hearing Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OPKO Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innerscope Hearing Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OPKO Health pays -- of its earnings as a dividend. Innerscope Hearing Technologies pays out -- of its earnings as a dividend.

OPKO Health quarterly revenues are $173.6M, which are larger than Innerscope Hearing Technologies quarterly revenues of --. OPKO Health's net income of $24.9M is higher than Innerscope Hearing Technologies's net income of --. Notably, OPKO Health's price-to-earnings ratio is -- while Innerscope Hearing Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health is 1.72x versus -- for Innerscope Hearing Technologies. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 14.34% compared to OPKO Health's net margin of 25.43%. OPKO Health's return on equity of -9.71% beat ResMed's return on equity of 23.76%.

OPKO Health has a consensus price target of --, signalling upside risk potential of 155.38%. On the other hand ResMed has an analysts' consensus of $206.05 which suggests that it could grow by 6.68%. Given that OPKO Health has higher upside potential than ResMed, analysts believe OPKO Health is more attractive than ResMed.

OPKO Health has a beta of 1.616, which suggesting that the stock is 61.573% more volatile than S&P 500. In comparison ResMed has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.593%.

OPKO Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.85% to investors and pays a quarterly dividend of $0.53 per share. OPKO Health pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

OPKO Health quarterly revenues are $173.6M, which are smaller than ResMed quarterly revenues of $1.2B. OPKO Health's net income of $24.9M is lower than ResMed's net income of $311.4M. Notably, OPKO Health's price-to-earnings ratio is -- while ResMed's PE ratio is 31.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health is 1.72x versus 7.28x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 14.34% compared to OPKO Health's net margin of -17.98%. OPKO Health's return on equity of -9.71% beat Xtant Medical Holdings's return on equity of -35.98%.

OPKO Health has a consensus price target of --, signalling upside risk potential of 155.38%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Xtant Medical Holdings has higher upside potential than OPKO Health, analysts believe Xtant Medical Holdings is more attractive than OPKO Health.

OPKO Health has a beta of 1.616, which suggesting that the stock is 61.573% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

OPKO Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OPKO Health pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

OPKO Health quarterly revenues are $173.6M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. OPKO Health's net income of $24.9M is higher than Xtant Medical Holdings's net income of -$5M. Notably, OPKO Health's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health is 1.72x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.